Blog
RSS FeedPosted by Michael Wonder on 11 Mar 2026
Tecvayli (teclistamab) monotherapy application submitted to the EMA for relapsed/refractory multiple myeloma after at least one prior therapy
10 March 2026 - Johnson & Johnson today announced the submission of a type II variation application to the EMA seeking ...
Posted by Michael Wonder on 10 Mar 2026
Cutting-edge cancer treatment research heading offshore as local patients miss out
11 March 2026 - Newsreader Will McDonald is six years into his fight with aggressive prostate cancer. He wants all Australians ...
Posted by Michael Wonder on 09 Mar 2026
Ipsen voluntarily withdraws Tazverik (tazemetostat) in follicular lymphoma and epithelioid sarcoma
9 March 2026 - Ipsen announced today that it is voluntarily withdrawing Tazverik (tazemetostat) in all indications from all Ipsen ...
Posted by Michael Wonder on 09 Mar 2026
Enhertu granted priority review in the US as post-neoadjuvant treatment for patients with HER2 positive early breast cancer
9 March 2026 - Based on DESTINY-Breast05 Phase 3 trial results, which showed Enhertu reduced the risk of invasive disease ...
Posted by Michael Wonder on 08 Mar 2026
Incyte announces the European Commission approval of Zynyz (retifanlimab) for the first-line treatment of advanced squamous cell carcinoma of the anal canal
6 March 2026 - The EC approval is based on results of the POD1UM-303 study which showed that adult patients with ...
Posted by Michael Wonder on 06 Mar 2026
Roche's Columvi, Takeda's Fruzaqla pass first review for Korea insurance coverage
5 March 2026 - Roche's DLBCL treatment Columvi (glofitamab) and Takeda's metastatic colorectal cancer treatment Fruzaqla (fruquintinib) have cleared the ...
Posted by Michael Wonder on 05 Mar 2026
FDA approves teclistamab in combination with daratumumab hyaluronidase-fihj for relapsed or refractory multiple myeloma
5 March 2026 - Today, the FDA approved teclistamab (Tecvayli, Janssen Biotech) in combination with daratumumab hyaluronidase-fihj for adult patients ...
Posted by Michael Wonder on 05 Mar 2026
New multi-indication PBS listing for two immunotherapy treatments from March 2026
1 March 2026 - Bristol Myers Squibb Australia confirms that Opdivo (nivolumab) and Yervoy (ipilimumab) will be listed on the ...
Posted by Michael Wonder on 05 Mar 2026
Dying father pleads for cancer drug subsidy to ‘keep being a dad’
5 March 2026 - A North Queensland mother has travelled to Canberra to beg the Federal Government to save her ...
Posted by Michael Wonder on 04 Mar 2026
J&J Korea receives reimbursement for Balversa in urothelial carcinoma
3 March 2026 - Johnson & Johnson Innovative Medicine Korea said it received reimbursement for Balversa (erdafitinib), a treatment for ...
Posted by Michael Wonder on 02 Mar 2026
World first cheaper immunotherapy treatment listing for patients with advanced or rare cancers
1 March 2026 - From today, thousands more Australians living with advanced and rare cancers will have access to affordable ...
Posted by Michael Wonder on 01 Mar 2026
New PBS listing for immunotherapy cancer drugs Opdivo and Yervoy to be slashed
2 March 2026 - Patients with advanced and rare cancers will be able to access two immunotherapy drugs for just $25, ...
Posted by Michael Wonder on 28 Feb 2026
Ontario becomes the first province to publicly reimburse the first targeted oral therapy for adults with grade 2 IDH-mutant glioma
27 February 2026 - Servier Canada announces Ontario coverage of Voranigo under the FAST program. ...
Posted by Michael Wonder on 27 Feb 2026
Enhertu supplemental new drug application submitted in Japan as adjuvant therapy for patients with HER2 positive early breast cancer
27 February 2026 - Submission based on DESTINY-Breast05 phase 3 trial results, which showed Enhertu reduced the risk of invasive ...
Posted by Michael Wonder on 26 Feb 2026
FDA grants accelerated approval to zongertinib for unresectable or metastatic non-squamous non-small cell lung cancer
26 February 2026 - Today, the FDA granted accelerated approval to zongertinib (Hernexeos, Boehringer Ingelheim Pharmaceuticals), a kinase inhibitor, for ...